Impact of Long-Term Dienogest Therapy on Quality of Life in Asian Women with Endometriosis: the Prospective Non-Interventional Study ENVISIOeN

The ENVISIOeN study ( NCT02425462 ) was a prospective, multicenter, international, noninterventional cohort study performed in 6 Asian countries at 36 sites (Republic of Korea: 12 sites, Indonesia: 10 sites, Thailand: 5 sites, Malaysia: 4 sites, Philippines: 3 sites, Singapore: 2 sites). The study was conducted in accordance with the Declaration of Helsinki and in compliance with Good Clinical Practice. The primary objective of the study was to determine the change in pain dimension of Endometriosis Health Profile-30 (EHP-30) after 6-month therapy with dienogest. The secondary objectives included change in EHP-30 scores at month 6 and 24, efficacy of dienogest in reducing EAPP at month 6, 12 and 24, patients’ and clinicians’ satisfaction with dienogest, assessment of endometriosis symptoms and bleeding pattern, and rates of dienogest discontinuation and repeated surgery. Data were collected during study visits at basline, and at months 1, 3, 6, 12, and 24 after start of dienogest therapy; all study visits occurred on site and within the routine clinical practice. Asian women aged ≥18 years with clinical diagnosis (by suggestive symptoms and positive finding of chocolate cyst on imaging) or surgical diagnosis of endometriosis and presence of EAPP were eligible to participate in the study. In this study, EAPP was defined as pain at menstruation, chronic pelvic pain irrelevant to menstruation, and/or dyspareunia. Further inclusion criteria were physician’s independent decision to newly prescribe dienogest and written informed consent provided by patient. Exclusion criteria were contraindication for dienogest use as per the summary of product characteristics (active venous thromboembolic disorder, arterial and cardiovascular disease, diabetes mellitus with vascular involvement, severe hepatic disease, liver tumors, known or suspected sex hormone-dependent malignancies, undiagnosed vaginal bleeding and hypersensitivity to the active substance or to any of the excipients) and participation in an investigational program with interventions outside of routine clinical practice. Patient were treated according to the respective national guidelines and in line with the American Society for Reproductive Medicine and/or European Society of Human Reproduction and Embryology guidelines. Enrolled patients were observed over the 24-month period, irrespective of whether they remained or discontinued dienogest, unless lost to follow up. Patients filled out the EHP-30 questionnaire at baseline and at month 6 and month 24. EHP-30 consists of the core instrument scales addressing pain, control and powerlessness, social support, emotional well-being, and self-image [ 26 – 28 ]. Additionally, supplementary module scales covering areas of work, relationship with children, sexual relationship, treatment, and infertility were used. Items for each scale were summed and transformed on a range from 0 (best possible HRQoL) to 100 (worst possible HRQoL). Patients evaluated EAPP using the numeric rating scale with scores ranging from 0 (no pain) to 10 (unbearable pain) at baseline and after 6 and 24 months of therapy with a 4-week recall period. Bleeding profile was analyzed across the following categories: normal bleeding (regular bleeding with normal flow and duration), irregular bleeding cycle (intermenstrual interval  35 days), amenorrhea (no menstruation during last 90 days), and intermenstrual spotting/bleeding (irregular episodes of bleeding, often light and short, occurring between otherwise fairly normal menstrual periods). Further assessments included the rate and reason for dienogest discontinuation, patients’ and physicians’ satisfaction with treatment, and pain recurrence and repeated surgery rates. Treatment-emergent adverse events (TEAE) and serious adverse events (SAE) were documented at each study visit. Analysis of efficacy was performed on the efficacy analysis set (EFF) that included all patients with evaluable primary outcome, i.e., EHP-30 questionnaires filled out at baseline and between week 12 and 36 after start of treatment (6-month visit) by patients who continued dienogest therapy. Measurements after dienogest discontinuation were excluded. Safety analyses were performed on the full analysis set (FAS) that comprised of all patients with at least one dose of dienogest. Data were analyzed using SAS release 9.4 (SAS Institute, Cary, NC, USA) and described by visit (baseline, 6- and 24-month visit) and by change from baseline. Continuous variables were summarized by mean (± standard deviation), median, minimum, maximum; and categorical variables as a number and percentage. 95% confidence intervals (CI) were provided for changes in EHP-30 scores. Missing data were not imputed. Incidence of TEAE and SAE was presented as the Medical Dictionary for Regulatory Activities (MedDRA) preferred terms by system organ class.

From April 2015 to August 2016, 895 patients at 36 sites were enrolled in the study (Fig.  1 ). 887 patients were included in FAS; 551 patients were included in EFF set. The mean duration of newly prescribed dienogest treatment in EFF set was 16.9 ± 7.6 months and the main reasons for end of observation were regular end of study (64.4%), lost to follow-up (23.1%) and relief of symptoms (6.7%). At month 6, the majority of patients continued treatment with dienogest (85.3%); 13.3% of patients discontinued the therapy, most often due to relief of symptoms (38.4%), adverse event (AE, 35.6%) or wish to conceive (9.6%). At month 24, dienogest therapy was continued by 44.2% of patients whereas 28.8% discontinued the dienogest, most frequently due to relief of symptoms (53.6%), physician decision (17.9%) or AE (14.3%). Fig. 1 CONSORT diagram. *One patient violated inclusion criteria: clinical or surgical diagnosis of endometriosis and endometriosis-associated pelvic pain, and four patients violated inclusion criterion decision taken by the physician to newly prescribe dienogest. **EHP-30 pain score was not evaluable at baseline and/or at study visit at month 6. EFF, efficacy analysis set; FAS, full analysis set CONSORT diagram. *One patient violated inclusion criteria: clinical or surgical diagnosis of endometriosis and endometriosis-associated pelvic pain, and four patients violated inclusion criterion decision taken by the physician to newly prescribe dienogest. **EHP-30 pain score was not evaluable at baseline and/or at study visit at month 6. EFF, efficacy analysis set; FAS, full analysis set 536 patients (60.4%) received endometriosis treatment prior to study start (Table  1 ); 454 (84.7%) among them underwent prior surgery and 186 women (34.7%) had previous hormonal treatment, most often gonadotropin-releasing hormone agonist (55.4%), followed by progestin plus estrogen-progestin combination (29.6%) and progestin alone (19.9%); 3.2% of patients received dienogest. Pain recurred in 28.2% of women with surgery (within 17.6 ± 21.2 months), and in 56.5% of patients with prior hormonal treatment (within 8.0 ± 11.9 months). Pain medication was given to 18.3% of patients ( n  = 98/536); mean time to pain recurrence was 9.7 ± 33.5 days. Table 1 Baseline characteristics Parameter Demography N years, mean ± SD   Age at registration 887 34.4 ± 7.6 History of endometriosis N %   Onset of first symptomsa     5 years ago 206 23.2     Missing 1 0.1   Most common symptoms of endometriosisb     Dysmenorrhea 720 81.2     Chronic pelvic pain 304 34.3     Dyspareunia 55 6.2     Subfertility 44 5.0   Time point of first diagnosisa     5 years ago 91 10.3   Method of diagnosisb     Surgical diagnosis 621 70.0     Clinical diagnosis 560 63.1   Endometriosis lesions (n = 777 evaluable patients)     Single 425 54.7     Multi 352 45.3   Endometriosis localization (n = 737 evaluable patients)b     Ovary 650 88.2     Pelvic organ 287 38.9     Extra pelvic 21 2.9 Prior endometriosis treatment N %   Patients without prior treatment 351 39.6   Patients with prior treatment 536 60.4     Type of treatment ( n  = 536) N %     Surgery 454 84.7     Hormonal treatment 186 34.7     Pain therapy 98 18.3 rASRM stage of endometriosis (n = 471) b,c N %   Stage I (minimal) 17 3.7   Stage II (mild) 25 5.5   Stage III (moderate) 92 20.3   Stage IV (severe) 130 28.6   Unknown 207 45.6 Most common previous diseases ( n  = 145) b N %   Uterine leiomyoma 71 49.0   Endometrial polyp 36 24.8   Ovarian cysts 26 17.9   Pelvic inflammatory disease 20 13.8 Most common concomitant diseases ( n  = 154) b N %   Adenomyosis 51 33.1   Uterine leiomyoma 42 27.3   Anemia 18 11.7 a Partially missing dates were imputed by the earliest possible time point: In case that only the day was missing, the date was imputed as the first day of the month. In case that the day and the month were missing, i.e., only the year was available, the day and month was imputed by January 1st b Multiple answers possible c rASRM was assessed for each individual surgery ( n  = 471 surgeries) in 454 patients with a prior surgical treatment for endometriosis. rASRM, revised American Society for Reproductive Medicine score Baseline characteristics a Partially missing dates were imputed by the earliest possible time point: In case that only the day was missing, the date was imputed as the first day of the month. In case that the day and the month were missing, i.e., only the year was available, the day and month was imputed by January 1st b Multiple answers possible c rASRM was assessed for each individual surgery ( n  = 471 surgeries) in 454 patients with a prior surgical treatment for endometriosis. rASRM, revised American Society for Reproductive Medicine score For 6-month and 24-month assessments, EHP-30 core instrument questionnaires were filled out on average at 178 ± 22.5 days ( n  = 486) and 713.2 ± 30.9 days (n = 98) after baseline visit, respectively, and EHP-30 modular instrument questionnaires were filled out on average 178 ± 22.2 days ( n  = 482) and 713.7 ± 30.4 days ( n  = 100) after baseline visit, respectively. Scores for all EHP-30 core and modular instrument scales improved during the first 6 months of dienogest therapy and continued to improve until month 24 (Tables  2 and 3 , respectively). Percentage of patients with improvement in EHP-30 scores was highest for scales Pain, and Control and powerlessness (Fig.  2 ). Table 2 EHP-30 core scores and changes from baseline Dimension N Mean SD Median Min; max 95%CI Nmiss Pain   Baseline 551 37.5 28.1 38.6 0; 100 – 0   Month 6 486 8.4 13.5 0 0; 65.9 – 0   Month 24 98 3.9 8.4 0 0; 38.6 – 55   Change from baseline at month 6 486 −28.9 27.5 −25 −100; 36.4 −31.35; −26.45 0   Change from baseline at month 24 98 −34 28.4 −30.7 −100; 29.6 −39.66; −28.29 55 Control and powerlessness   Baseline 550 35.3 28.1 33.3 0; 100 – 1   Month 6 485 11.4 16.2 4.2 0; 87.5 – 1   Month 24 98 5.7 9.9 0 0; 58.3 – 55   Change from baseline at month 6 484 −23.7 28.2 −18.8 −100; 58.3 −26.23; −21.19 2   Change from baseline at month 24 97 −28.5 26.2 −29.2 −100; 25 −33.81; −23.23 56 Emotional well-being   Baseline 549 32.3 25.9 29.2 0; 100 – 2   Month 6 485 17.3 20.3 8.3 0; 91.7 – 1   Month 24 98 9.8 16.8 0 0; 75 – 55   Change from baseline at month 6 484 −15 26.7 −10.4 −100; 79.2 −17.35; −12.57 2   Change from baseline at month 24 98 −20.6 22.8 −20.8 −70.8; 33.3 −25.19; −16.05 55 Social support   Baseline 550 27.7 25.8 25 0; 100 – 1   Month 6 486 14.4 19.8 6.3 0; 87.5 – 0   Month 24 98 8.4 18 0 0; 100 – 55   Change from baseline at month 6 487 −13.2 27 −6.3 −100; 87.5 −15.56; −10.75 0   Change from baseline at month 24 98 −17.9 24.3 −12.5 −87.5; 43.8 −22.79; −13.05 55 Self-image   Baseline 550 20.6 24.9 8.3 0; 100 – 1   Month 6 486 11.7 18.9 0 0; 91.7 – 0   Month 24 98 7.1 17.3 0 0; 100 – 55   Change from baseline at month 6 486 −8.4 26.4 0 −100; 91.7 −10.76; −6.05 0   Change from baseline at month 24 98 −13.9 23.2 −8.3 −83.3; 50 −18.52; −9.20 55 Table 3 EHP-30 modular scores and changes from baseline Dimension N Mean SD Median Min; max 95%CI Nmiss N/A* Work   Baseline 475 30.4 27.1 30 0; 100 – 13 63   Month 6 431 7.5 13.6 0 0; 80 – 7 46   Month 24 86 2.8 8.8 0 0; 60 – 54 14   Change from baseline at month 6 395 −22.4 25.4 −15 −90; 40 −24.88; −19.86 89   Change from baseline at month 24 81 −25.4 25 −20 −90; 35 −30.89; −19.85 73 Relationship with children   Baseline 189 25.5 30.4 0 0; 100 – 27 335   Month 6 188 6.7 14.7 0 0; 75 – 29 267   Month 24 41 2.4 7 0 0; 25 – 17 96   Change from baseline at month 6 140 −18.5 29.4 0 −100; 50 −23.39; −13.57 344   Change from baseline at month 24 30 −25.8 28.6 −25 −100; 12.5 −36.51; −15.15 124 Sexual intercourse   Baseline 353 28.1 26.8 25 0; 100 – 79 119   Month 6 303 15 20.5 5 0; 95 – 36 145   Month 24 66 11.1 18.3 0 0; 75 – 62 26   Change from baseline at month 6 258 −13.1 26.4 −5 −90; 75 −16.29; −9.82 226   Change from baseline at month 24 52 −17.8 27.5 −10 −75; 40 −25.45; −10.17 102 Treatment   Baseline 383 19.9 22.7 16.7 0; 100 – 31 137   Month 6 447 11.2 16.3 0 0; 83.3 – 6 31   Month 24 92 6.9 13 0 0; 75 – 54 8   Change from baseline at month 6 322 −7.2 22.4 0 −91.7; 50 −10.43; −3.96 162   Change from baseline at month 24 70 −11.6 25.2 0 −91.7; 50 −17.56; −5.53 84 Infertility   Baseline 317 29 28.8 25 0; 100 – 36 198   Month 6 308 20.2 24.1 12.5 0; 100 – 23 153   Month 24 59 14.2 18.3 6.3 0; 81.3 – 57 38   Change from baseline at month 6 235 −8.9 21.9 0 −100; 56.3 −11.69; −6.07 249   Change from baseline at month 24 47 −11.4 19.4 −12.5 −75; 31.3 −17.14; −5.73 107 *Not applicable to the respective issue during the last 4 weeks Fig. 2 Changes in core EHP-30 scores from baseline to month 6 and to month 24. Results demonstrate proportions of patients with deterioration, no change and improvement defined as >0, 0 and < 0 difference in EHP-30 scores between baseline and visit at month 6 and 24. Data were analyzed in patients with evaluable score changes after 6 (n = 486, scales pain, social support, self-image; n = 484, scales control and powerlessness and emotional well-being) and after 24 months of therapy (n = 98, scales pain, emotional well-being, social support and self-image; n  = 97, scale control and powerlessness). EHP-30, Endometriosis Health Profile-30 questionnaire EHP-30 core scores and changes from baseline EHP-30 modular scores and changes from baseline *Not applicable to the respective issue during the last 4 weeks Changes in core EHP-30 scores from baseline to month 6 and to month 24. Results demonstrate proportions of patients with deterioration, no change and improvement defined as >0, 0 and < 0 difference in EHP-30 scores between baseline and visit at month 6 and 24. Data were analyzed in patients with evaluable score changes after 6 (n = 486, scales pain, social support, self-image; n = 484, scales control and powerlessness and emotional well-being) and after 24 months of therapy (n = 98, scales pain, emotional well-being, social support and self-image; n  = 97, scale control and powerlessness). EHP-30, Endometriosis Health Profile-30 questionnaire EAPP assessment at month 6 and month 24 was performed on average 175.6 ± 22.6 days ( n  = 484) and 701.1 ± 41 days ( n  = 154) after baseline visit. EAPP score improved during the first 6 months of therapy and remained stable thereafter (Table  4 ). Patients with baseline EAPP >4 had a greater mean EAPP score change than those with baseline EAPP ≤4 during therapy. Patients not taking rescue medication (defined as any medication for pain management used while on treatment with dienogest) showed a tendency towards an improved EAPP compared to those taking the rescue medication (note that only a few patients were included in the latter category). Type of diagnosis (surgical vs only clinical) and prior surgical or hormonal treatment had no impact on efficacy of dienogest to alleviate EAPP (Table 4 ). More than 90% of patients had an improvement in EAPP at both post-baseline study visits (Fig.  3 ). Amelioration of EAPP was more often experienced at month 6 by women with a higher baseline EAPP severity (>4), and at month 24 by those with a lower baseline EAPP (≤4). Table 4 EAPP scores and changes from baseline Parameter N Mean SD Median Min, max Nmiss Total Baseline 551 5.6 2.8 6 0; 10 0 Month 6 484 1 1.4 0 0; 7 2 Month 24 154 0.7 1.3 0 0; 9 0 Change from baseline at month 6 484 −4.6 3 −5 −10; 5 2 Change from baseline at month 24 154 −4.6 3 −5 −10; 3 0 Surgical diagnosis* Baseline 396 5.3 2.8 6 0; 10 0 Month 6 346 1 1.4 0 0; 7 2 Month 24 106 0.8 1.3 0 0; 5 0 Change from baseline at month 6 346 −4.3 2.8 −4 −10; 4 2 Change from baseline at month 24 106 −4.5 3 −5 −10; 3 0 Clinical diagnosis only Baseline 155 6.3 2.7 7 0; 10 0 Month 6 138 1 1.5 0 0; 6 0 Month 24 48 0.6 1.4 0 0; 9 0 Change from baseline at month 6 138 −5.3 3.2 −6 −10; 5 0 Change from baseline at month 24 48 −4.8 3.1 −5 −10; 2 0 Baseline severity of EAPP ≤4 Baseline 185 2.3 1.2 2 0; 4 0 Month 6 163 0.8 1.3 0 0; 6 1 Month 24 65 0.6 1.1 0 0; 5 0 Change from baseline at month 6 163 −1.5 1.7 −1 −4; 5 1 Change from baseline at month 24 65 −1.8 1.6 −2 −4; 3 0 Baseline severity of EAPP >4 Baseline 366 7.3 1.6 7 5; 10 0 Month 6 321 1 1.5 0 0; 7 1 Month 24 89 0.8 1.5 0 0; 9 0 Change from baseline at month 6 321 −6.2 2.1 −6 −10; 1 1 Change from baseline at month 24 89 −6.6 2 −7 −10; 0 0 Previous surgical or hormonal treatment Baseline 329 5.3 2.7 6 0; 10 0 Month 6 283 0.9 1.4 0 0; 7 2 Month 24 93 0.6 1.1 0 0; 5 0 Change from baseline at month 6 283 −4.4 2.8 −5 −10; 3 2 Change from baseline at month 24 93 −4.3 2.7 −4 −9; 1 0 No previous surgical or hormonal treatment Baseline 222 6 2.8 6 0; 10 0 Month 6 201 1 1.4 0 0; 6 0 Month 24 61 0.9 1.6 0 0; 9 0 Change from baseline at month 6 201 −4.9 3.2 −5 −10; 5 0 Change from baseline at month 24 61 −5 3.5 −5 −10; 3 0 Use of rescue medication Baseline 55 6.7 2.6 8 0; 10 0 Month 6 13 2.9 1.8 3 0; 5 0 Month 24 3 2.3 1.2 3 1; 3 0 Change from baseline at month 6 13 −3.2 3.4 −3 −10; 4 0 Change from baseline at month 24 3 −2.7 5.1 −4 −7; 3 0 No use of rescue medication Baseline 496 5.5 2.8 6 0; 10 0 Month 6 471 0.9 1.4 0 0; 7 0 Month 24 151 0.7 1.3 0 0; 9 0 Change from baseline at month 6 471 −4.7 3 −5 −10; 5 0 Change from baseline at month 24 151 −4.6 3 −5 −10; 3 0 *Includes patients, who only had surgical diagnosis as well as surgical + clinical diagnosis. EAPP, endometriosis-associated pelvic pain Fig. 3 Changes in EAPP from baseline to month 6 and to month 24 among all patients included in efficacy analysis set ( a ) and according to type of diagnosis ( b ) and baseline EAPP severity ( c ). Data shown are proportions of patients with deterioration, no change and improvement defined as > 0, 0 and < 0 difference in EAPP scores between baseline and visits at months 6 and 24. *Including patients with surgical diagnosis only and surgical and clinical diagnosis. **0.3% of patients each had no change, improvement or missing data on change of EAPP. EAPP, endometriosis-associated pelvic pain EAPP scores and changes from baseline *Includes patients, who only had surgical diagnosis as well as surgical + clinical diagnosis. EAPP, endometriosis-associated pelvic pain Changes in EAPP from baseline to month 6 and to month 24 among all patients included in efficacy analysis set ( a ) and according to type of diagnosis ( b ) and baseline EAPP severity ( c ). Data shown are proportions of patients with deterioration, no change and improvement defined as > 0, 0 and < 0 difference in EAPP scores between baseline and visits at months 6 and 24. *Including patients with surgical diagnosis only and surgical and clinical diagnosis. **0.3% of patients each had no change, improvement or missing data on change of EAPP. EAPP, endometriosis-associated pelvic pain Pain recurrence rate in EFF set was approximately three times higher in patients discontinuing (8.3%, n  = 8/97) than among women continuing dienogest treatment for up to 24 months (2.7%, n  = 4/146). Median time from dienogest discontinuation to pain recurrence was 22.2 months (Q1–Q3: 22.2–22.2). Share of patients with normal bleeding decreased while the rate of amenorrhea increased during the 24-month therapy period (Fig.  4 ). The percentage of patients with irregular bleeding and intermenstrual spotting/bleeding increased during the first 6 months of therapy and then returned to baseline levels at month 24. Fig. 4 Bleeding patterns at the baseline, month 6 and month 24. The bleeding patterns were defined as follows: normal bleeding: regular bleeding with normal flow and duration; irregular bleeding cycle: bleeding cycle less than 21 days or more than 35 days; amenorrhea: no menstruation during last 90 days; intermenstrual spotting/bleeding: irregular episodes of bleeding, often light and short, occurring between otherwise fairly normal menstrual periods Bleeding patterns at the baseline, month 6 and month 24. The bleeding patterns were defined as follows: normal bleeding: regular bleeding with normal flow and duration; irregular bleeding cycle: bleeding cycle less than 21 days or more than 35 days; amenorrhea: no menstruation during last 90 days; intermenstrual spotting/bleeding: irregular episodes of bleeding, often light and short, occurring between otherwise fairly normal menstrual periods 66.6% of patients ( n  = 515/773 of FAS) and 67.7% ( n  = 523/773) of physicians at month 6 and 52.3% ( n  = 191/365) of both patients and physicians at month 24 were very satisfied or somewhat satisfied with dienogest. At month 6 and month 24, only 4.5% and 2.5% of patients, and 2.1% and 1.9% of physicians were dissatisfied with treatment. 83.7% ( n  = 407/486 of EFF) and 87.0% of patients ( n  = 134/154) reported improved of symptoms at month 6 and month 24, respectively. Only 1.0% and 1.3% of patients reported that their symptoms worsened at month 6 and month 24, respectively. The proportion of patients receiving another or no treatment increased from 1.1% at month 6 to 27.1% at month 24. Surgery was repeated in two out of 273 patients that received a surgery prior to dienogest, including one patient (1.3%) among the 77 patients who stopped dienogest and one patient (0.5%) in the group of 196 patients that continued therapy until month 24. TEAEs, predominantly of mild-to-moderate intensity, were reported by 45.9% of patients ( n  = 407/887). TEAEs occurring in at least 1% of patients are presented in Table  5 . Table 5 Treatment-emergent adverse events observed in at least 1% of patients TEAE (MedDRA PT) N % Any TEAE 407 45.9 Vaginal hemorrhage 95 10.7 Metrorrhagia 75 8.5 Amenorrhea 65 7.3 Weight increased 41 4.6 Menstruation irregular 39 4.4 Headache 33 3.7 Acne 23 2.6 Alopecia 23 2.6 Depression 16 1.8 Menorrhagia 16 1.8 Insomnia 13 1.5 Abdominal pain 12 1.4 Dizziness 12 1.4 Uterine hemorrhage 10 1.1 Breast tenderness 9 1 MedDRA Medical Dictionary for Regulatory Activities, PT preferred term, TEAE Treatment-emergent adverse event Treatment-emergent adverse events observed in at least 1% of patients MedDRA Medical Dictionary for Regulatory Activities, PT preferred term, TEAE Treatment-emergent adverse event A total of 616 drug-related TEAEs were documented in 39.9% of patients ( n  = 354/887), most often vaginal hemorrhage (defined as any bloody discharge outside of normal menstrual cycle, including prolonged or irregular bleeding/spotting, in 10.4% of patients), metrorrhagia (defined as abnormal bleeding between regular menstrual periods, in 7.3%) and amenorrhea (6.4%). 63 patients (7.1%) discontinued dienogest therapy due to drug-related TEAEs. Abnormal uterine bleeding (MedDRA preferred terms: metrorrhagia, menorrhagia, vaginal or uterine hemorrhage) was the most prominent reason for discontinuation (2.0%, n  = 18/887). Eleven SAEs were reported in nine patients (Table  6 ). Anemia and menorrhagia (two events each) were the most common SAEs. Ten events were classified as serious because they required hospitalization and one case of anemia was an important medical event. All SAEs were recovered or resolved. Table 6 All documented serious adverse events SAE (MedDRA PT) N % Any SAE 9 1 Anemia 2 0.2 Menorrhagia 2 0.2 Vomiting* 1 0.1 Asthenia* 1 0.1 Bartholin’s abscess 1 0.1 Leptospirosis 1 0.1 Peritonitis 1 0.1 Dysmenorrhea* 1 0.1 Ovarian cyst 1 0.1 *Drug-related SAE. MedDRA Medical Dictionary for Regulatory Activities, PT preferred term, SAE serious adverse event All documented serious adverse events *Drug-related SAE. MedDRA Medical Dictionary for Regulatory Activities, PT preferred term, SAE serious adverse event

The results of the ENVISIOeN study indicate that dienogest improves patient-reported HRQoL and EAPP in the real-life setting in Asian women with endometriosis diagnosed either clinically or surgically. Given that observed safety profile was consistent with the previous results and that satisfaction with the treatment was high, dienogest might be a promising first-line treatment option for the long-term management of only clinically diagnosed patients with debilitating endometriosis-associated symptoms.

Almost half of women with endometriosis are dissatisfied with their medical treatment [ 29 , 30 ]. This indicates that there is an unmet need for therapeutic approaches effective in alleviating disease symptoms and maintaining good HRQoL. Although surgery is efficacious in alleviating endometriosis symptoms and improving HRQoL, 40% to 50% of patients have symptom recurrence, with 47% needing reoperation [ 31 – 34 ]. For these reasons, several guidelines recommend empirical long-term medicinal treatment and taking into account specific needs and expectations of the patient [ 2 , 7 , 35 – 37 ]. In our study, we found that dienogest improved scores for all EHP-30 scales already at month 6 of treatment, with continuous improvement until month 24. Similarly, continuous improvements in EHP-30 scores were noted in adolescents over the 12-month dienogest therapy [ 22 ]. In long-term, dienogest improved all EHP-30 core scores in patients with rectosigmoid endometriosis treated for 36 months [ 38 ]. Furthermore, 6-month treatment with dienogest increased HRQoL in patients who had a pain persistence and were unsatisfied with norethisterone acetate therapy [ 39 ]. In addition to EHP-30 questionnaire, Caruso and colleagues reported an improved HRQoL as assessed by SF-36 questionnaire in patients treated with dienogest for 6 months [ 20 ]. That study also demonstrated an increased sexual function and reduced sexual distress following the therapy. Collectively, these data indicate that dienogest rapidly improves HRQoL and is effective in a long-term. Moreover, EAPP scores improved during 6 months of dienogest therapy, and this effect was maintained over the entire observation period. Thus, our results confirm data on EAPP from other observational studies investigating long-term dienogest therapy. For example, in the study by Park et al., EAPP decreased by 33.5 mm on visual analog scale during 12 months of therapy [ 40 ] while Römer reported a decrease in EAPP of 50 mm after 60 months of treatment [ 41 ]. Furthermore, in a large open-label extension study following a 12-week placebo-controlled trial, EAPP decrease amounted to 43.2 mm at week 65 [ 15 ]. Rate of patients with EAPP reduction in our study (over 91% of patients) was slightly lower than previously reported in clinical trials (96.7% to 97.1%) [ 40 , 42 ]. Furthermore, patients with baseline EAPP score > 4 had a more pronounced pain reduction than those with baseline EAPP score ≤ 4. Interestingly, percentage of patients with improvement in pain scores decreased from month 6 to month 24 among those with baseline EAPP score > 4 and increased in those with score ≤ 4. On the one hand, these data indicate that a longer duration of dienogest therapy is required to alleviate EAPP in patients with low baseline EAPP score. On the other hand, some patients with a higher initial EAPP severity might require rescue medication during therapy. The latter notion is supported by the fact that only a few patients had documented use of rescue medication. A lower EAPP improvement in that group compared with patients not taking rescue medication stresses the need for appropriate pain management in patients with severe EAPP. Furthermore, prior treatment (surgery or hormonal therapy) and type of diagnosis (surgical or clinical) had no impact on magnitude of EAPP improvement. Similarly, no difference in EAPP reduction between patients with or without surgery was reported in the study by Römer et al. [ 41 ]. This suggests that dienogest is efficacious in reducing EAPP in both first- and later lines of therapy and it is an optimal choice when access to surgical diagnostic techniques like laparoscopy is limited. Several guidelines now emphasize the value of non-invasive clinical diagnosis based on clinical symptoms and patient’s history, especially in low-resource setting [ 2 , 35 , 37 ]. Collectively, our results support a new paradigm that the diagnosis of endometriosis does not always require histological data, but with appropriate clinical approaches and empirical therapy, we can induce long-term improvements in quality of life in [ 2 , 7 , 35 – 37 ]. This approach would be even better if we succeeded in having non-invasive endometriosis diagnostic markers [ 43 – 45 ]. Reduction in severity of EAPP potentially contributed to the fact that 66.6% of patients after month 6 and 52.3% after month 24 were satisfied with dienogest therapy. Similar or even higher rates of satisfaction with dienogest therapy were reported by European patients [ 22 , 41 , 46 ]. Considering that 40% to 45.5% of women with endometriosis are dissatisfied with their current treatment, data accumulated thus far suggest that dienogest largely meets expectations of patients regarding their treatment [ 29 , 30 ]. Analysis of TEAE revealed that rate of patients with depression was similar or lower than previously reported (1.8% vs 2.0% to 82.9%, [ 18 , 22 , 38 , 41 , 42 ]). Furthermore, fewer patients reported headache than in other studies (3.7% vs 9.0% to 12.5%, [ 18 , 22 , 41 , 42 ]). Rates of weight gain, acne and alopecia were slightly lower or similar as previously reported [ 22 , 38 , 42 ]. Only 1% of patients had SAE, mostly anemia and menorrhagia. 39.9% of patients had drug-related TEAE while previous studies reported either higher or lower rates of drug-related AE (15.3% to 100%, [ 15 , 22 , 46 , 47 ]). It should be noted however, that dienogest was used at various doses in these studies and most of reported drug-related AE were non-serious. Yu et al. reported lower rates for dienogest-related vaginal hemorrhage and amenorrhea (1.8%, both, vs 10.4% and 6.4%, respectively, in our study [ 46 ]). Conversely, Harada et al. demonstrated a higher frequency of genital bleeding (95%, [ 47 ]). Overall, the share of patients with normal bleeding profile decreased while proportion of patients with amenorrhea increased during the study which is in line with current evidence on dienogest profile [ 7 , 15 , 17 , 18 , 42 , 48 ]. Therefore, physicians should inform patients about potential abnormal uterine bleedings which could occur during long-term treatment with progestins. The key strengths of our study are the large sample size spanning 6 Asian countries and the long duration of follow-up. Additionally, by using disease-specific patient-reported outcome measures, we captured the patients’ perspective on changes in HRQoL during therapy. Furthermore, broad inclusion criteria ensured collection of real-world evidence in unselected population of patients treated with dienogest. Our study has also several limitations. The number of patients included in the efficacy analysis decreased from month 6 to month 24, therefore, results from the latter time-point may not be representative to all investigated patients. Furthermore, due to international setting of this study, differences between the healthcare systems could affect the diagnosis or type of rescue treatment of endometriosis. Finally, the observational nature of this study precluded the comparison of efficacy and safety between dienogest and other medicines for endometriosis.

Endometriosis affects approximately 10% of women in the reproductive age, with a prevalence of up to 50% in infertile women [ 1 , 2 ]. The prevalence of endometriosis varies by race and ethnicity with Asian women (particularly in East Asian countries) more likely to be affected by this disease than Caucasians [ 1 , 3 – 5 ]. The most common clinical signs of endometriosis are menstrual irregularities, chronic pelvic pain, dysmenorrhea, dyspareunia and infertility [ 6 ]. Symptoms of endometriosis often affect psychological and social functioning of patients. For this reason, endometriosis is considered as a disabling condition that may significantly reduce health-related quality of life (HRQoL). Previous studies demonstrated that endometriosis has a negative impact on social relationships, sexuality, mental health, and work productivity [ 7 – 10 ]. Furthermore, poor HRQoL is observed particularly in patients suffering from a more severe pelvic pain [ 10 – 12 ]. Importantly, hormonal therapy and surgical treatment may improve HRQoL and reduce pelvic pain in patients with endometriosis [ 13 ]. Dienogest is an oral progestin approved for endometriosis treatment in 157 countries, including 15 countries in Asia [ 7 ]. Dienogest is an attractive option for prolonged treatment due to a moderate suppression of estrogen levels and a low androgenic, mineralocorticoid, or glucocorticoid activity [ 14 ]. Long-term studies in Europe and Japan demonstrated that dienogest is efficacious in reducing pelvic pain, well tolerated and has a good safety profile [ 15 – 17 ]. Although several clinical trials demonstrated improvements in HRQoL following the dienogest therapy, the real-world evidence is scarce [ 18 – 24 ]. Our interim analysis of non-interventional study ENVISIOeN demonstrated an improved HRQoL and reduced endometriosis-associated pelvic pain (EAPP) after 6 months of dienogest therapy in clinically or surgically diagnosed Asian women with endometriosis [ 25 ]. In this manuscript, we report the final analysis of HRQoL, EAPP and safety in patients receiving dienogest for up to 24 months within the ENVISIOeN study.